Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) – Pipeline Review, H1 2017’, provides in depth analysis on Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60)Additionally, the report provides an overview of key players involved in Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Cardiovascular, Immunology, Metabolic Disorders and Ophthalmology under development targeting Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60)

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60)

The report reviews Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) targeted therapeutics and enlists all their major and minor projects

The report assesses Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Conatus Pharmaceuticals Inc

Shire Plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC

3.4.22.60) - Overview

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC

3.4.22.60) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC

3.4.22.60) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC

3.4.22.60) - Companies Involved in Therapeutics Development

Conatus Pharmaceuticals Inc

Shire Plc

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC

3.4.22.60) - Drug Profiles

BaxB-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BaxG-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BaxM-159 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emricasan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emricasan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate Caspases for Diabetic Retinopathy, Age Related Macular Degeneration and Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC

3.4.22.60) - Dormant Products

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC

3.4.22.60) - Discontinued Products

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC

3.4.22.60) - Product Development Milestones

Featured News & Press Releases

Nov 14, 2016: Conatus Announces Poster Presentations at AASLD Annual Meeting

Nov 03, 2016: Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis

Oct 03, 2016: Conatus Pharmaceuticals Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting

May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial

Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data

Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting

Feb 03, 2016: FDA Grants Conatus Fast Track Designation for Development of Emricasan in NASH Cirrhosis

Jan 11, 2016: Conatus Initiates Phase 2b ENCORE-NF Clinical Trial of Emricasan in Patients With NASH Fibrosis

Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial

Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting

Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting

Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting

Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting

Sep 23, 2015: Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis

Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indication, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Conatus Pharmaceuticals Inc, H1 2017

Pipeline by Shire Plc, H1 2017

Dormant Projects, H1 2017

Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports